
Nanologica Q1 2025 - Limited near-term visibility but sales ramp up to be expected in H2

Redeye updates its outlook on Nanologica, continuing to anticipate a considerable sales ramp-up in H2. Although limited near-term visibility weighs on the share price—currently trading in line with our bear case—we argue the case remains solid, supported by multiple catalysts.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Nanologica Q1 2025 - Limited near-term visibility but sales ramp up to be expected in H2](#)